BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11. [PMID: 15376305 DOI: 10.1002/lt.20237] [Cited by in Crossref: 194] [Cited by in F6Publishing: 171] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 16.5] [Reference Citation Analysis]
2 Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248:857-862. [PMID: 18948815 DOI: 10.1097/sla.0b013e3181896278] [Cited by in Crossref: 137] [Cited by in F6Publishing: 52] [Article Influence: 10.5] [Reference Citation Analysis]
3 Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1-15. [PMID: 18217899 DOI: 10.1111/j.1399-0012.2007.00739.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 48] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wall WJ. Hepatocellular cancer, transplantation, and sirolimus. Liver Transpl 2004;10:1312-4. [DOI: 10.1002/lt.20283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
5 Shah M, Shankar A, Gee I, Nash K, Hoare M, Gibbs P, Davies S, Alexander GJM. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients. Aliment Pharmacol Ther 2015;41:379-92. [DOI: 10.1111/apt.13049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.Ann Surg. 2020;272:855-862. [PMID: 32889867 DOI: 10.1097/SLA.0000000000004280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
7 Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother 2007;8:1275-82. [PMID: 17563262 DOI: 10.1517/14656566.8.9.1275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Jonas S, Mittler J, Pascher A, Schumacher G, Theruvath T, Benckert C, Rudolph B, Neuhaus P. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl. 2007;13:896-903. [PMID: 17538994 DOI: 10.1002/lt.21189] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
9 Belghiti J. Transplantation for liver tumors. Semin Oncol. 2005;32:29-32. [PMID: 16360010 DOI: 10.1053/j.seminoncol.2005.07.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
10 Jonas S, Mittler J, Pascher A, Theruvath T, Thelen A, Klupp J, Langrehr JM, Neuhaus P. Extended indications in living-donor liver transplantation: bile duct cancer. Transplantation. 2005;80:S101-S104. [PMID: 16286884 DOI: 10.1097/01.tp.0000187106.29908.2b] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
11 Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162-1168. [PMID: 17496530 DOI: 10.1097/01.tp.0000262607.95372.e0] [Cited by in Crossref: 137] [Cited by in F6Publishing: 114] [Article Influence: 9.8] [Reference Citation Analysis]
12 Sevmis S, Karakayali H, Ozçay F, Canan O, Bilezikci B, Torgay A, Haberal M. Liver transplantation for hepatocellular carcinoma in children. Pediatr Transplant 2008;12:52-6. [PMID: 18186889 DOI: 10.1111/j.1399-3046.2007.00777.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
13 Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, Onaca N, Goldstein R, Levy M, Klintmalm GB. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2009;15:1834-1842. [PMID: 19938137 DOI: 10.1002/lt.21953] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 9.5] [Reference Citation Analysis]
14 Parolin MB, Coelho JCU, Matias JEF, Baretta GAP, Ioshii SO, Nardo H. Resultados do transplante hepático em pacientes com diagnóstico pré-operatório de hepatocarcinoma. Arq Gastroenterol 2006;43:259-64. [DOI: 10.1590/s0004-28032006000400003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
16 Vivarelli M, Risaliti A. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol. 2011;17:4741-4746. [PMID: 22147974 DOI: 10.3748/wjg.v17.i43.4741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bashir MR, Hussain HK. Imaging in Patients with Cirrhosis. Radiologic Clinics of North America 2015;53:919-31. [DOI: 10.1016/j.rcl.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Saran U, Foti M, Dufour J. Cellular and molecular effects of the mTOR inhibitor everolimus. Clinical Science 2015;129:895-914. [DOI: 10.1042/cs20150149] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
19 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
20 Bhardwaj N, Perera MT, Silva MA. Current Treatment Approaches to HCC with a Special Consideration to Transplantation. J Transplant 2016;2016:7926264. [PMID: 27413539 DOI: 10.1155/2016/7926264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
21 Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640-1648. [PMID: 16598777 DOI: 10.1002/lt.20707] [Cited by in Crossref: 105] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis]
22 Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 380] [Article Influence: 48.7] [Reference Citation Analysis]
23 Fisher RA, Maluf DG, Wolfe L, Williams B, Cotterell A, Stravitz RT, Heuman D, Posner M. Is hepatic transplantation justified for primary liver cancer? J Surg Oncol 2007;95:674-9. [PMID: 17477383 DOI: 10.1002/jso.20617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
24 Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, Zafrani ES, Mallat A, Duvoux C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis. 2012;44:610-616. [PMID: 22459565 DOI: 10.1016/j.dld.2012.02.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
25 Soll C, Clavien PA. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression? Hepatology 2010;51:1113-5. [PMID: 20373365 DOI: 10.1002/hep.23582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Thelen A, Neuhaus P. Liver transplantation for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:469-475. [PMID: 17909715 DOI: 10.1007/s00534-006-1196-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
27 Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009;9:247-261. [PMID: 19192962 DOI: 10.1586/14737140.9.2.247] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
28 Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant. 2009;9:2851-2854. [PMID: 20021481 DOI: 10.1111/j.1600-6143.2009.02860.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
29 Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91. [PMID: 17335296 DOI: 10.2165/00003495-200767030-00004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 123] [Article Influence: 10.9] [Reference Citation Analysis]
30 Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715-722. [PMID: 19002496 DOI: 10.1007/s00432-008-0506-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
31 Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A, Mueller-Brand J, Hofmann M, Schmid KW, Gerken G, Broelsch CE. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl 2006;12:1089-96. [PMID: 16799958 DOI: 10.1002/lt.20755] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
32 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
33 Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007;83:425-432. [PMID: 17318075 DOI: 10.1097/01.tp.0000252780.42104.95] [Cited by in Crossref: 112] [Cited by in F6Publishing: 101] [Article Influence: 8.0] [Reference Citation Analysis]
34 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432. [PMID: 17597707 DOI: 10.1038/ncponc0844] [Cited by in Crossref: 191] [Cited by in F6Publishing: 165] [Article Influence: 13.6] [Reference Citation Analysis]
35 Andreou A, Gül S, Pascher A, Schöning W, Al-Abadi H, Bahra M, Klein F, Denecke T, Strücker B, Puhl G. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2015;17:168-175. [PMID: 25263399 DOI: 10.1111/hpb.12345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Fujiki M, Aucejo F, Kim R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? Clin Transplant 2013;27:169-77. [PMID: 23216662 DOI: 10.1111/ctr.12042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
37 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
38 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 95] [Article Influence: 23.6] [Reference Citation Analysis]
39 Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11:1420-1425. [PMID: 15770715 DOI: 10.3748/wjg.v11.i10.1420] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
40 Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:62-69. [PMID: 21964956 DOI: 10.1002/lt.22441] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 12.1] [Reference Citation Analysis]
41 Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol 2021:S0748-7983(21)00407-8. [PMID: 33902956 DOI: 10.1016/j.ejso.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Scherer MN, Banas B, Mantouvalou K, Schnitzbauer A, Obed A, Krämer BK, Schlitt HJ. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg 2007;392:511-23. [DOI: 10.1007/s00423-007-0188-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
43 Chan SC, Fan ST. Historical perspective of living donor liver transplantation. World J Gastroenterol 2008;14:15-21. [PMID: 18176956 DOI: 10.3748/wjg.14.15] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
44 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
45 Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:411-419. [PMID: 23278125 DOI: 10.1111/apt.12185] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
46 Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation. 2009;87:157-163. [PMID: 19155967 DOI: 10.1097/tp.0b013e318193886e] [Cited by in Crossref: 105] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
47 Pei F, Shang K, Jiang B, Wang H, Mei F, Zhang Y, Du J, Zhong H, You J. Clinicopathologic study on complications of orthotopic liver transplantation in 54 patients with chronic hepatitis B viral infection. Hepatol Int 2013;7:468-76. [DOI: 10.1007/s12072-013-9422-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
49 Karakayali H, Moray G, Sozen H, Dalgic A, Emiroglu R, Haberal M. Expanded Criteria for Liver Transplantation in Patients With Hepatocellular Carcinoma. Transplantation Proceedings 2006;38:575-8. [DOI: 10.1016/j.transproceed.2006.01.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
50 Neipp M, Schwarz A, Pertschy S, Klempnauer J, Becker T. Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up. Clin Transplant. 2006;20:147-150. [PMID: 16640518 DOI: 10.1111/j.1399-0012.2005.00455.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
51 Lerut J. Carcinome hépatocellulaire et transplantation hépatique : état des lieux. Journal de Chirurgie 2007;144:105-10. [DOI: 10.1016/s0021-7697(07)89481-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Roberts RJ, Wells AC, Unitt E, Griffiths M, Tasker AD, Allison ME, Bradley JA, Watson CJ. Sirolimus-induced pneumonitis following liver transplantation. Liver Transpl 2007;13:853-6. [DOI: 10.1002/lt.21141] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
53 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
54 Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, Varo-Pérez E. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma. Transplant Proc. 2011;43:711-713. [PMID: 21486580 DOI: 10.1016/j.transproceed.2011.01.090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
56 Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-34. [PMID: 17111055 DOI: 10.1155/2006/238218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hurtova M, Decaens T, Laurent A, Cherqui D, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire et chez les malades avec antécédents de cancer. La Presse Médicale 2009;38:1272-80. [DOI: 10.1016/j.lpm.2009.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Kawahara T, Toso C, Yamaguchi K, Cader S, Douglas DN, Nourbakhsh M, Lewis JT, Churchill TA, Yagita H, Kneteman NM. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. Liver Int 2013;33:1441-8. [DOI: 10.1111/liv.12275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23:155-168. [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
60 Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13:543-551. [PMID: 17394152 DOI: 10.1002/lt.21078] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
61 Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167-1198. [PMID: 17521218 DOI: 10.2165/00003495-200767080-00006] [Cited by in Crossref: 244] [Cited by in F6Publishing: 187] [Article Influence: 17.4] [Reference Citation Analysis]
62 Olson JC, Wiesner RH. Immunomodulating therapy in liver transplantation: principles and practice. Immunotherapy 2012;4:793-805. [PMID: 22947008 DOI: 10.2217/imt.12.69] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
63 Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80:S254-S264. [PMID: 16251858 DOI: 10.1097/01.tp.0000186382.81130.ba] [Cited by in Crossref: 389] [Cited by in F6Publishing: 288] [Article Influence: 24.3] [Reference Citation Analysis]
64 Heuer M, Benkö T, Cicinnati V, Kaiser G, Sotiropoulos G, Baba H, Treckmann J, Broelsch C, Paul A. Effect of Low-Dose Rapamycin on Tumor Growth in Two Human Hepatocellular Cancer Cell Lines. Transplantation Proceedings 2009;41:359-65. [DOI: 10.1016/j.transproceed.2008.10.090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
65 Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int. 2010;30:1247-1258. [PMID: 20602682 DOI: 10.1111/j.1478-3231.2010.02303.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 8.0] [Reference Citation Analysis]
66 Ozçay F, Canan O, Bilezikçi B, Torgay A, Karakayali H, Haberal M. Effect of living donor liver transplantation on outcome of children with inherited liver disease and hepatocellular carcinoma. Clin Transplant. 2006;20:776-782. [PMID: 17100729 DOI: 10.1111/j.1399-0012.2006.00571.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
67 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
68 Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
69 Gomez-camarero J, Salcedo M, Rincon D, Iacono OL, Ripoll C, Hernando A, Sanz C, Clemente G, Bañares R. Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms. Transplantation 2007;84:786-91. [DOI: 10.1097/01.tp.0000280549.93403.dd] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
70 Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncology 2011;7:1149-67. [DOI: 10.2217/fon.11.95] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 11.8] [Reference Citation Analysis]
71 Benten D, Sterneck M, Panse J, Rogiers X, Lohse AW. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008;14:789-98. [DOI: 10.1002/lt.21434] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
72 Presser SJ, Schumacher G, Neuhaus R, Thuss-Patience P, Stieler J, Neuhaus P. De novo esophageal neoplasia after liver transplantation. Liver Transpl. 2007;13:443-450. [PMID: 17318861 DOI: 10.1002/lt.21058] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
73 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003-12021. [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
74 Lee JO, Kim DY, Lim JH, Seo MD, Yi HG, Oh DY, Im SA, Kim TY, Bang YJ. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. J Gastroenterol Hepatol. 2009;24:800-805. [PMID: 19175825 DOI: 10.1111/j.1440-1746.2008.05672.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
75 Koehl GE, Schlitt HJ, Geissler EK. Rapamycin and tumor growth: mechanisms behind its anticancer activity. Transplantation Reviews 2005;19:20-31. [DOI: 10.1016/j.trre.2005.01.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
76 Vallin M, Sturm N, Lamblin G, Guillaud O, Hilleret M, Hervieu V, Joubert J, Abergel A, Leroy V, Boillot O, Dumortier J, Scoazec J. Unrecognized intrahepatic cholangiocarcinoma: an analysis of 993 adult cirrhotic liver explants. Clin Transplant 2013;27:403-9. [DOI: 10.1111/ctr.12108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
77 Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the α-fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population. Transplantation 2018;102:1316-22. [PMID: 29470357 DOI: 10.1097/TP.0000000000002136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
78 Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388-398. [PMID: 21168455 DOI: 10.1016/j.jhep.2010.10.044] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 7.5] [Reference Citation Analysis]
79 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14:633-638. [PMID: 18324656 DOI: 10.1002/lt.21420] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
80 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
81 Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [PMID: 29167827 DOI: 10.21037/tgh.2017.09.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
82 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36 Suppl 1:124-129. [PMID: 26725909 DOI: 10.1111/liv.13028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
83 Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int. 2008;21:207-217. [PMID: 18069922 DOI: 10.1111/j.1432-2277.2007.00610.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
84 Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J Hepatol. 2011;55:1441-1451. [PMID: 21781947 DOI: 10.1016/j.jhep.2011.06.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
85 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 160] [Article Influence: 28.2] [Reference Citation Analysis]
86 Xu S, Zhang Y, Wang G, Yang Q, Liu B, Zhang J, Li H, Wang G, Yang Y, Chen G. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:674-81. [DOI: 10.1016/j.clinre.2016.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
87 Geissler EK. Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol. 2015;12:705-717. [PMID: 26483298 DOI: 10.1038/nrclinonc.2015.186] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
88 Palmes D, Zibert A, Budny T, Bahde R, Minin E, Kebschull L, Hölzen J, Schmidt H, Spiegel HU. Impact of rapamycin on liver regeneration. Virchows Arch. 2008;452:545-557. [PMID: 18398622 DOI: 10.1007/s00428-008-0604-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
89 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
90 Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C. Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006;12:1761-1769. [PMID: 16964590 DOI: 10.1002/lt.20884] [Cited by in Crossref: 140] [Cited by in F6Publishing: 113] [Article Influence: 10.0] [Reference Citation Analysis]
91 Lo C. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion. Am J Transplant. 2008;8:2485-2486. [PMID: 19032218 DOI: 10.1111/j.1600-6143.2008.02466.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
92 Livraghi T, Brambilla G, Carnaghi C, Tommasini MA, Torzilli G. Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol. 2010;102:868-876. [PMID: 20886553 DOI: 10.1002/jso.21733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
93 Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009;15:4225-4233. [PMID: 19750565 DOI: 10.3748/wjg.15.4225] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
94 Dalgic A, Karakayali H, Moray G, Emiroglu R, Sozen H, Torgay A, Haberal M. Liver Transplantation and Tacrolimus Monotherapy for Hepatocellular Carcinoma With Expanded Criteria. Transplantation Proceedings 2005;37:3154-6. [DOI: 10.1016/j.transproceed.2005.06.096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
95 Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 2006;20:1-18. [DOI: 10.1016/j.trre.2005.10.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
96 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
97 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
98 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
99 Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc. 2008;40:3548-3553. [PMID: 19100435 DOI: 10.1016/j.transproceed.2008.03.165] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
100 Zhang W, Jambulingam P, Silva M, Taniere P, Bramhall S, Mayer A, Buckels J, Mirza D. Orthotopic liver transplantation for epithelioid haemangioendothelioma. European Journal of Surgical Oncology (EJSO) 2007;33:898-901. [DOI: 10.1016/j.ejso.2007.01.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
101 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 279] [Article Influence: 35.6] [Reference Citation Analysis]
102 Zhou J, Huang Z, Chen Z, Xu F, Tong R, Zheng S. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database. BMC Gastroenterol 2021;21:195. [PMID: 33931011 DOI: 10.1186/s12876-021-01786-6] [Reference Citation Analysis]
103 Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013;19:9174-9182. [PMID: 24409045 DOI: 10.3748/wjg.v19.i48.9174] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
104 Elshamy M, Aucejo F, Menon KV, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016;8:874-80. [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
105 Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Román A, Serón D, Ussetti P; ATOS Working Group. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 2012;26:261-79. [PMID: 22902168 DOI: 10.1016/j.trre.2012.07.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
106 Pini LA, Gallesi D, Brovia D, Bertolini A, Pinetti D, Ruggieri V, Pisa S, Poppi B, Nives Castellana C. Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: comparison of methods. J Clin Lab Anal 2006;20:239-44. [PMID: 17115421 DOI: 10.1002/jcla.20148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
107 Schöniger-hekele M, Müller C. Pilot study: rapamycin in advanced hepatocellular carcinoma: Rapamycin in patients with hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010;32:763-8. [DOI: 10.1111/j.1365-2036.2010.04404.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
108 González-Rodriguez A, Alba J, Zimmerman V, Kozma SC, Valverde AM. S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology 2009;50:216-29. [PMID: 19437488 DOI: 10.1002/hep.22915] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
109 Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005. [PMID: 20639898 DOI: 10.1038/onc.2010.236] [Cited by in Crossref: 562] [Cited by in F6Publishing: 516] [Article Influence: 51.1] [Reference Citation Analysis]
110 Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol. 2005;56:87-99. [PMID: 15979889 DOI: 10.1016/j.critrevonc.2004.12.011] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
111 Vivarelli M, Vetrone G, Zanello M, Barba GL, Cucchetti A, Lauro A, Grazi GL, Pinna AD. Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature. Transplant Int 2006;19:1022-5. [DOI: 10.1111/j.1432-2277.2006.00381.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
112 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
113 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
114 Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol. 2013;19:6077-6083. [PMID: 24106409 DOI: 10.3748/wjg.v19.i36.6077] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
115 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
116 Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res. 2010;159:705-713. [PMID: 19482307 DOI: 10.1016/j.jss.2008.07.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
117 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
118 Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11:497-503. [PMID: 15838913 DOI: 10.1002/lt.20391] [Cited by in Crossref: 138] [Cited by in F6Publishing: 126] [Article Influence: 8.6] [Reference Citation Analysis]
119 Watson CJ, Bradley JA. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplantation Reviews 2006;20:104-14. [DOI: 10.1016/j.trre.2006.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
120 Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation. Hepatology 2011;53:1570-9. [DOI: 10.1002/hep.24231] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
121 Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P, Bianchi G, Tamè MR, Gaudio MD, Ravaioli M, Cescon M, Grazi GL, Pinna AD. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010;42:2579-84. [PMID: 20832548 DOI: 10.1016/j.transproceed.2010.04.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
122 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Zarrinpar A, Busuttil RW. Immunomodulating options for liver transplant patients. Expert Rev Clin Immunol 2012;8:565-78; quiz 578. [PMID: 22992151 DOI: 10.1586/eci.12.47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
124 Pleguezuelo M, Germani G, Burroughs AK. Liver Transplantation: Prevention and Treatment of Rejection. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 685-723. [DOI: 10.1002/9781444314403.ch42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
125 Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190. [PMID: 20459775 DOI: 10.1186/1471-2407-10-190] [Cited by in Crossref: 118] [Cited by in F6Publishing: 92] [Article Influence: 10.7] [Reference Citation Analysis]
126 Hollebecque A, Decaens T, Boleslawski E, Mathurin P, Duvoux C, Pruvot FR, Dharancy S. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol. 2009;33:361-369. [PMID: 19398289 DOI: 10.1016/j.gcb.2009.02.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
127 Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-2596. [PMID: 17868066 DOI: 10.1111/j.1600-6143.2007.01965.x] [Cited by in Crossref: 348] [Cited by in F6Publishing: 302] [Article Influence: 24.9] [Reference Citation Analysis]
128 Lei J, Yan L. Outcome Comparisons Among the Hangzhou, Chengdu, and UCSF Criteria for Hepatocellular Carcinoma Liver Transplantation after Successful Downstaging Therapies. J Gastrointest Surg 2013;17:1116-22. [DOI: 10.1007/s11605-013-2140-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
129 Emre S, Umman V, Rodriguez-davalos M. Current concepts in pediatric liver tumors: Current concepts in pediatric liver tumors. Pediatric Transplantation 2012;16:549-63. [DOI: 10.1111/j.1399-3046.2012.01704.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
130 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Reference Citation Analysis]
131 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transplant Int 2007;20:747-53. [DOI: 10.1111/j.1432-2277.2007.00505.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
132 Toso C, Patel S, Asthana S, Kawahara T, Girgis S, Kneteman NN, Shapiro AM, Bigam DL. The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation. Clin Transplant. 2010;24:695-700. [PMID: 20002466 DOI: 10.1111/j.1399-0012.2009.01159.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
133 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
135 Pacheco-moreira L, Balbi E, Enne M, Cerqueira A, Miecznikowski R, Matuck T, Pereira J, Carvalho D, Martinho J. One Living Donor and Two Donations: Sequential Kidney and Liver Donation With 20-Years Interval. Transplantation Proceedings 2005;37:4337-8. [DOI: 10.1016/j.transproceed.2005.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
136 Macdonald AS. Cancer and Transplantation Intersect at the Mammalian Target of Rapamycin. Transplantation 2007;84:682-4. [DOI: 10.1097/01.tp.0000280548.99241.c4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
137 Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006;20 Suppl 17:30-43. [PMID: 17100699 DOI: 10.1111/j.1399-0012.2006.00598.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
138 Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011;25:28-34. [PMID: 21258665 DOI: 10.1155/2011/201019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
139 Hara T, Eguchi S, Yoshizumi T, Akamatsu N, Kaido T, Hamada T, Takamura H, Shimamura T, Umeda Y, Shinoda M, Ogura Y, Fukumoto T, Kasahara M, Hibi T, Umeshita K, Furukawa H, Ohdan H. Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: A multi-center study in Japan. J Hepatobiliary Pancreat Sci. 2021;28:346-352. [PMID: 33464720 DOI: 10.1002/jhbp.896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Lee KW, Seo YD, Oh SC, Suh SW, Jeong J, Kim H, Yi NJ, Suh KS. What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma? Hepatol Res 2016;46:593-600. [PMID: 26348114 DOI: 10.1111/hepr.12588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Castroagudín J, Molina E, Varo E. Calcineurin Inhibitors in Liver Transplantation: To Be or Not to Be. Transplantation Proceedings 2011;43:2220-3. [DOI: 10.1016/j.transproceed.2011.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
142 Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007;41:839-54. [DOI: 10.1097/mcg.0b013e318060ac52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
143 Decaens T, Duvoux C. Carcinome hépatocellulaire et transplantation hépatique : rôle futur des inhibiteurs de la mTOR. Gastroentérologie Clinique et Biologique 2009;33:S257-62. [DOI: 10.1016/s0399-8320(09)73163-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Klintmalm GB, Nashan B. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant. 2014;2014:845438. [PMID: 24719752 DOI: 10.1155/2014/845438] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
145 Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 2008;13:66-70. [PMID: 18307022 DOI: 10.1007/s10147-007-0733-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 7.8] [Reference Citation Analysis]
146 Sanchez Antolín G, Garcia Pajares F, Lorenzo Pelayo S, Herranz Bachiller MT, Almohalla C, Velicia R, Caro Paton A. Indications and effectiveness of the mammalian target of rapamycin in liver transplantation. Transplant Proc. 2011;43:714-717. [PMID: 21486581 DOI: 10.1016/j.transproceed.2011.01.105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
147 Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opin Drug Metab Toxicol 2011;7:1535-46. [PMID: 22032293 DOI: 10.1517/17425255.2011.631911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
148 Earl TM, Chapman WC. Transplantation for hepatocellular carcinoma: the North American experience. Recent Results Cancer Res 2013;190:145-64. [PMID: 22941019 DOI: 10.1007/978-3-642-16037-0_10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
149 Macdonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Review of Clinical Immunology 2014;3:423-36. [DOI: 10.1586/1744666x.3.3.423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
151 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
152 Moray G, Karakayali F, Yilmaz U, Ozcay F, Bilezikci B, Haberal M. Expanded Criteria for Hepatocellular Carcinoma and Liver Transplantation. Transplantation Proceedings 2007;39:1171-4. [DOI: 10.1016/j.transproceed.2007.02.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
153 Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opinion on Emerging Drugs 2006;11:469-87. [DOI: 10.1517/14728214.11.3.469] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
154 Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol. 2014;6:776-782. [PMID: 25429315 DOI: 10.4254/wjh.v6.i11.776] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
155 Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl. 2011;17 Suppl 2:S6-13. [PMID: 21858912 DOI: 10.1002/lt.22423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
156 Calmus Y, Durrbach A. Everolimus de novo in liver transplantation. Gastroenterol Clin Biol. 2009;33 Suppl 4:S247-S252. [PMID: 20004330 DOI: 10.1016/s0399-8320(09)73161-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
157 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014;20:15007-17. [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
158 Levy GA. Progress in Transplantation. Therapeutic Drug Monitoring 2010;32:246-9. [DOI: 10.1097/ftd.0b013e3181dca981] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
159 Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016;100:116-25. [PMID: 26555945 DOI: 10.1097/TP.0000000000000965] [Cited by in Crossref: 189] [Cited by in F6Publishing: 76] [Article Influence: 37.8] [Reference Citation Analysis]
160 Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51:1237-1243. [PMID: 20187107 DOI: 10.1002/hep.23437] [Cited by in Crossref: 217] [Cited by in F6Publishing: 193] [Article Influence: 19.7] [Reference Citation Analysis]
161 Mullath A, Krishna M. Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg 2019;11:287-95. [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World J Gastroenterol 2006;12:3114-8. [PMID: 16718799 DOI: 10.3748/wjg.v12.i19.3114] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
163 Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course! J Hepatol. 2005;43:569-573. [PMID: 16120470 DOI: 10.1016/j.jhep.2005.07.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
164 Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol 2015;11:2923-36. [PMID: 26414336 DOI: 10.2217/fon.15.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
165 Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation. 2010;89:733-738. [PMID: 20048692 DOI: 10.1097/tp.0b013e3181c7dcc0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
166 Schnitzbauer AA, Schlitt HJ, Geissler EK. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation. 2011;91:1173-1176. [PMID: 21427632 DOI: 10.1097/tp.0b013e318215e72b] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
167 Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2013;2:22-30. [PMID: 24570911 DOI: 10.3978/j.issn.2304-3881.2012.11.03] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
168 Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: Is immunosuppression a factor? Liver Transpl 2005;11:494-6. [DOI: 10.1002/lt.20413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
169 Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, Sotiropoulos GC, Takeda A, Beckebaum S, Schmitz KJ. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. 2009;29:399-405. [PMID: 18492014 DOI: 10.1111/j.1478-3231.2008.01798.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
170 Decaens T, Hurtova M, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2009;33:61-9. [DOI: 10.1016/j.gcb.2008.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Cotler SJ, Hay N, Xie H, Chen ML, Xu PZ, Layden TJ, Guzman G. Immunohistochemical Expression of Components of the Akt-mTORC1 Pathway is Associated with Hepatocellular Carcinoma in Patients with Chronic Liver Disease. Dig Dis Sci 2008;53:844-9. [DOI: 10.1007/s10620-007-9934-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]